U.S. PATENT DOCUMENTS 8/1979 2/1980 8/1980 9/1982 10/1982 8/1983 2/1984 6/1984 4/1985 6/1985 6/1985 10/1985 2/1986 9/1986 12/1986 1/1987 1/1987 1/1987 3/1987 4/1987 7/1987 10/1987 3/1988 11/1988 5/1989 6/1989 6/1989 9/1989 1/1990 3/1990 Cooley. In a further embodiment of the present invention, the foam material may be provided in a sleeve that fits over the jaws 20 and 40 of the stapler. Suitable designs for sleeves are described in U.S. Pat. Nos. 5, 503, 638; 5, 702.409; and 5, 766,  188, which are hereby incorporated herein by reference. It is only necessary that the foam material be used on the portion of the sleeve that will remain in the patient for hemostasis or pneumostasis; the other portions of the sleeve may be made from other Suitable materials.
In accordance with preferred embodiments of the invention, foam material StripS 52 are preferably made from a compliant bioabsorbable foam material. The foam material uniformly distributes preSSure along the Staple line to cause Substantial hemostasis or pneumoStasis along the tissue cut. The foam material also provides a medium for the Staples to hold on to in the case of thin or diseased tissue. The material also absorbs impact and reduces trauma.
Suitable foam materials for use as a buttress material need to be compliant and pliable So that the foam may distribute the compressive load and compensate for variations in tissue thickness, thereby acting as an effective gasket for hemo Stasis and pneumostasis.
Suitable foams for use in the present invention are pre pared from biocompatible elastomeric polymers, preferably this polymer will also be bioabsorbable. Examples of Suit able bioabsorbable elastomers are described in U.S. Pat. No. 5,468,253 hereby incorporated by reference. Preferably the bioabsorbable biocompatible elastomers are based on ali phatic polyester, including but not limited to those Selected from the group consisting of elastomeric copolymers of e-caprolactone and glycolide (preferably having a mole ratio Preferably, the elastomers will exhibit a high percent elongation and a low modulus, while possessing good ten Sile Strength and good recovery characteristics. In the pre ferred embodiments of this invention, the elastomer from which the foams are formed will exhibit a percent elongation greater than about 200 preferably greater than about 500. It will also exhibit a modulus (Young's Modulus) of less than about 80,000 psi, preferably less than about 40,000 psi. There properties, which measure the degree of elasticity of the bioabsorbable elastomer, are achieved while maintaining a tensile Strength greater than about 500 psi, preferably greater than about 1,000 psi, and a tear Strength of greater than about 50 lbs/inch, preferably greater than about 80 lbs/inch. These elastomer polymers may be foamed by lyophilization, Supercritical Solvent foaming (i.e., as described in EP 464,163 B1), gas injection extrusion, gas injection molding or casting with an extractable material (i.e., Salts, Sugar or any other means known to those skilled in the art). Currently it is preferred to prepare bioabsorbable, biocompatible elastomers by lyophilization. One suitable method for lyophilizing elastomeric polymers to form foams is described in Example 2. Pharmaceutically active com pounds may be incorporated into the foam material to further treat the patient including are but not limited to antibiotics, antifungal agents, hemostatic agents, antiinflam matory agents, growth factors and the like. an integer in the range of from 1 to 7; and y is an integer in the range of from about 10 to about 20,000; blends of a viscous PEG liquid and a low melting solid PEG (solid at room temperature that melts at less than about 60° C.); biocompatible monosaccharides, disaccharides and polysac charides (such as pectin) that may be mixed with a plasti cizer (Such as glycerine) to form a tacky adhesive and biocompatible proteins (such as gelatin) that may mixed with a plasticizer (Such as glycerine) to form a tacky adhesive. S Many nontoxic bioabsorbable aliphatic ester polymers that are Semi-crystalline Solids or tacky liquids at room temperature may be used as a releasable adhesive. The releasable adhesive of this invention are generally charac terized as being flowable at body temperature (37° C) and preferably will flow at room temperatures (25 C.). Most preferably these liquids will have a low yield point to avoid migration of the polymer. Examples of Suitable tacky liquid copolymers are contained in U.S. patent application Ser. No. 08/746,180, filed Nov. 6, 1996 hereby incorporated by reference. Additionally, tacky microdispersions may also be used Such as those described in U.S. Pat. No. 5, 599, 852,  hereby incorporated by reference. In particular liquid copolymers composed of in the range of from about 65 mole percent to about 35 mole percent of e-caprolactone, trim ethylene carbonate, ether lactone (which for the purpose of this invention is defined to be 1,4-dioxepan-2-one and 1,5-dioxepan-2-one) repeating units or combinations thereof with the remainder of the polymer being a plurality of Second lactone repeating units are preferred. The Second lactone repeating units will be Selected from the group consisting of glycolic acid repeating units, lactic acid repeat ing units, 1,4-dioxanone repeating units, 6,6-dialkyl-1,4-dioxepan-2-one, combinations thereof and blends thereof. Additionally, e-caprolactone, trimethylene carbonate, or an ether lactone may be copolymerized to provide a liquid copolymer. Preferred polymers for use as particulate Solids are bioabsorbable polymers including homopolymers of poly(e-caprolactone), poly(p-dioxanone), or poly (trimethylene carbonate), copolymers of e-caprolactone and trimethylene carbonate, copolymers of e-caprolactone and a plurality of Second lactone repeating units. The Second lactone repeating units may be selected from the group consisting of glycolic acid repeating units, lactic acid repeat ing units, 1,4-dioxanone repeating units, 1,4-dioxepan-2-one repeating units, 1,5-dioxepan-2-one repeating units and combinations thereof. The copolymers of e-caprolactone will preferably be composed of from 99 mole percent to 70 mole percent e-caprolactone with the remainder of the polymer being a plurality of Second lactone repeating units. The polymerS may be linear, branched, or Star branched; block copolymers or terpolymers, Segmented block copoly merS or terpolymers. These polymers will also be purified to Substantially remove unreacted monomers that may cause an inflammatory reaction in tissue.
Preferred liquid copolymers for use as the releasable adhesive are composed of in the range of from about 65 mole percent to about 35 mole percent e-caprolactone or an ether lactone repeating unit with the remainder of the copolymer being trimethylene carbonate repeating units. Examples of Suitable terpolymers are terpolymerS Selected from the group consisting of poly(glycolide-co-ecaprolactone-co-p-dioxanone) and poly(lactide-co ecaprolactone-co-p-dioxanone) wherein the mole percent of e-caprolactone repeating units is from about 35 to about 65 mole percent.
Preferred are terpolymers having in the range of from 40 to 60 mole percent of e-caprolactone repeating units. Examples of liquid copolymer for use as the releasable adhesive may be Selected from the group consisting of poly(e-caprolactone-co-trimethylene carbonate), poly (lactide-co-trimethylene carbonate), poly(e-caprolactone co-p-dioxanone), poly(trimethylene carbonate-co-pdioxanone), poly(e-caprolactone-co-lactide), poly(lactide co-1,5-dioxepan-2-one), and poly(1,5-dioxepan-2-one-co-pdioxanone), poly(lactide-co-1,4-dioxepan-2-one), and poly (1,4-dioxepan-2-one-co-p-dioxanone). The mole percent of e-caprolactone, trimethylene carbonate or ether lactone repeating units in these polymers should be in the range of from about 35 to about 65 mole percent and preferably in the range of from 40 to 60 mole percent. Most preferably these liquid polymers will be Statistically random copolymers. These polymers will also be purified to substantially remove unreacted monomers that may cause an inflammatory reac tion in tissue.
The polymers used as the releasable adhesive should have an inherent Viscosity as determined in a 0.1 g/dL Solution of hexafluoroisopropanol (HFIP) at 25 C. ranging from about 0.1 dL/g to about 0.8 dL/g, preferably from about 0.1 dL/g to about 0.6 dL/g, and most preferably from 0.15 dL/g to 0.25 dL/g for liquid polymers.
Additionally formed. After these Solutions are allowed to cool and the resulting mixture may be tested for tackineSS and used if the desired tackineSS is obtained used in the present invention. Alternatively biocomptaible monosaccharides, disaccharides, polysaccharides or proteins can be used with a biocompatible plasticizer Such as glycerine to form tacky films in the presence of water. These materials may be applied to the Surface of the buttress material and activated by applying water before contacting with the Staple applier.
The amount of releasable adhesive that will be applied depends on a variety of factorS Such as the releasable adhesive used the desired degree of resistance desired for the foam to release and the geometry of its application. Those skilled in the art will readily be able to determine the appropriate amount of releasable adhesive to apply to achieve the desired release profile.
Additionally, it may be desired for porous foams to be Subsequently processed to avoid wicking of the adhesive into the interior of the foam. To prevent or minimize the wicking of the releasable adhesive into the porous foam it is desirable to use Seal the Surface of the porous foam. There are many methods that can be employed to Seal the Surface. For example top coating the foam with a low melting biocompatible material before applying the releasable adhe Sive. Alternatively the porous foam could be top coated with a film layer. Further the porous foam could be treated with a Solvent Solution to collapse the external layer of pores and form a skin. A similar effect could be achieved by applying a hot Surface to the porous foam to Substantially reduce the porosity of the Surface of the foam.
The aliphatic poly(ester)S are generally prepared by a ring opening polymerization of the desired proportions of one or more lactone monomers in the presence of an organometal lic catalyst and an initiator at elevated temperatures. The organometallic catalyst is preferably a tin-based catalyst, 7 e.g. Stannous Octoate, and is present in the monomer mixture at a molar ratio of monomer to catalyst ranging from about 15,000/1 to about 80,000/1. The initiator is typically an alkanol (Such as 1-dodecanol), a polyol (Such as 1,2-propanediol, 1,3-propanediol, diethylene glycol, or glycerol, poly(ethylene glycol)S, poly(propylene glycol)S and poly (ethylene-co-propylene glycol)S), a hydroxyacid, or an amine, and is present in the monomer mixture at a molar ratio of monomer to initiator ranging from about 100/1 to about 5000/1. The polymerization is typically carried out at a temperature range from about 80 to about 220 C., preferably 160 to 190° C., until the desired molecular weight and Viscosity are achieved.
The method for achieving hemostasis along a tissue cut having open blood vessels in accordance with the invention will now be discussed along with a discussion of the operation of Stapling After the firing wedges 32 are fully advanced to form all of the staples in cartridge 50, the pusher block and knife blade assembly 30 is returned to its start position by retrac tion of firing knob 42. The latch member 38 may then be moved to its unlatched position, Separating jaws 20 and 40, so as to permit the device 10 to be unclamped and removed from the tissue Sections releasing the foam material Strips from the anvil tip 62 and/or cartridge 50.
As shown in FIGS. 5 and 6, staples 51 extend through the foam material strips 52 and the tissue segments 70 and 72 sandwiched therebetween. The foam material strips 52 uni formly distribute pressure along the line of Staples and thereby cause Substantial hemostasis and pneumoStasis along the tissue cut and around the Staple legs. The absorb able nature of the material from which the foam strips are made allows the strips to be left in the body and eliminates the potential for foreign body reactions that might occur if the foams were not bioabsorbable.
In accordance with the most preferred embodiment of the invention the foam material is positioned adjacent the Sur faces of the tissue Sections that contact both the Staple cartridge 50 and the anvil tip 62. However, the invention contemplates that the foam material may be positioned adjacent only one of Such Surfaces, preferably the Surface adjacent the anvil tip 62. Further, it is preferred that a pair of parallel lines of Staples extend through each tissue Section adjacent the tissue cut. The method and apparatus of the invention in its broadest aspects is not limited to the Specific details shown and described, and modifications may be made to the disclosed; preferred embodiments of the invention without departing from the principles of the invention. tional 30 minutes, purged with nitrogen gas, and kept under a nitrogen gas blanket during the polymerization. The flask was placed in an oil bath. The oil bath temperature was raised to 80° C. and was held at 80° C. for 4 hour to completely dissolve the glycolide. The oil temperature was then raised to 190° C. and held for 18 hours. The flask was removed from the oil bath and allowed to cool to room temperature. The copolymer was devolatilized after replac ing the mechanical Stirrer with a magnetic Stirbar for 16 hours at 80 under full vacuum. The finished copolymer was characterized by 1H NMR and inherent viscosity in HFIP (at 25 C. and a concentration of 0.1 g/dL). The NMR results were polygylcolide, 47.3%, polycaprolactone 52.3% residual glycolide monomer less than 0.2%, residual capro lactone monomer less than 0.2%. The IV was 0.19.
EXAMPLE 2 Lyophilization ProceSS for Making Caprolactone
Glycolide Foams This example describes a preferred method for making lyophilized foam from caprolactone-glycolide copolymers.
Making Solution: An appropriate amount (16.5 gm) of polymer (nominal 40/60 CAP/GLY made in a manner simi lar to the methods described in U.S. Pat. No. 5,468,253) was placed in 1,4-dioxane Solvent (148 ml) and stirred at about 50° C. for about 5 hours until dissolved (to make a 10 weight percent Solution). The Solution was filtered cool through an extra coarse porosity filter (Kimble, Kimax Buchner funnel with Kimflow fritted disc, 150 ml capacity, extra coarse porosity-or equivalent) to remove undissolved polymer.
Lyophilization: An appropriate amount of Solution (31.0 g for about a 0.030" thick) was placed in a specially made flat bottom glass dish (constructed from "optically flat glass bottom and tube) about 8.5" in diameter. The dish was cleaned with caustic and Silanized before use. The dish containing the Solution was placed on the shelf of the precooled lyophilizer maintained at 20° C. The solution was then allowed to freeze by setting the shelf temperature to -5 C.
After 30 minutes a vacuum was pulled (in one case as long as 1 hour). Two hours of primary drying at -5°C. under
Vacuum was needed to remove most of the 1,4-dioxane. At the end of this drying phase, typically the vacuum level reaches to about 10 mTorr or less. Next the second phase of the drying was done in two stages under a 10 mTorr vacuum. First the shelf temperature was raised to 5 C. and held for 1 hour, then the temperature was raised to 20 C. and held for an additional 1 hour.
At the end of the Second drying phase the chamber was taken to room temperature and the vacuum was broken with nitrogen. The foams are removed from the dishes and placed in plastic bags and Stored under nitrogen.
The total cycle time for lyophilization was approximately 4.5 hours. Foams made by this process were determined to have <0.2 ppm of residual dioxane by headspace analysis. 8. The apparatus of claim 7 wherein the bioabsorbable releasable adhesive is Selected from the group consisting of copolymers of e-caprolactone and trimethylene carbonate, copolymers of e-caprolactone and an ether lactone, copoly mers of trimethylene carbonate and an ether lactone, copoly mers composed of in the range of from about 65 mole percent to about 35 mole percent of e-caprolactone, trim ethylene carbonate, ether lactone repeating units or combi nations thereof with the remainder of the polymer being a plurality of Second lactone repeating units, wherein the Second lactone repeating units being Selected from the group consisting of glycolide repeating units, lactide repeating units, 1,4-dioxanone repeating units, 6,6-dialkyl-1,4-dioxepan-2-one, combinations thereof and blends thereof.
9. The apparatus of claim 7 wherein the bioabsorbable releasable adhesive is a blend of liquid and low melting polyethylene glycols. 
